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Abstract
Engaging in physical activity (PA) is a key aspect in the management of axial spondyloarthritis (axial SpA), however, its 
relationship with clinical measures is unknown. Previous research has mainly focused on subjective methods of measuring 
PA and sedentary behaviour (SB). The aim of this study was to explore the associations between objectively measured PA 
and SB with clinical measures in people with established axial SpA. Fifty participants were recruited from secondary-care 
rheumatology outpatient services in Glasgow, UK. Clinical measures collected included; Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis 
Metrology Index (BASMI), Ankylosing Spondylitis Quality of Life (ASQOL) and the Six Minute Walk Test (6MWT). PA 
and SB were measured using the activPAL3 tri-axial accelerometer. Data from forty-five participants were included (23 
males, average age 49 ± 12 years). Participants accumulated an average of 93.2 ± 41.5 min/day walking with an average of 
7200 ± 3397 steps/day. The majority of the day (65%) was spent sitting, accumulated in prolonged bouts. Walking time and 
steps taken/day were associated with better BASFI (r = − 0.395, p = 0.007 and r = − 0.404, p = 0.006), ASQOL (r = − 0.375, 
p = 0.011 and r = − 0.361, p = 0.015) and 6MWT (r = 0.396, p = 0.007 and r = 0.421, p = 0.004); while longer walking events 
were associated with better BASMI (rho = − 0.352, p = 0.018), BASFI (rho = − 0.316, p = 0.034) and 6MWT (rho = 0.404, 
p = 0.006). SB was associated with worse ASQOL (r = 0.380, p = 0.010) and 6MWT (6MWT, r = − 0.357, p = 0.016). In 
people with axial SpA PA is associated with better function, exercise capacity and spinal mobility, while SB is associated 
with lower exercise capacity and poor quality of life. These findings support the promotion of PA and reduction of SB in 
people with axial SpA.
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Introduction
Axial spondyloarthritis (axial SpA), including ankylosing 
spondylitis and non-radiographic axial SpA, is a chronic 
inflammatory arthritis characterised by reduced spinal 
mobility and function and an increased risk of cardiovascular 
events [1, 2]. A combination of pharmacological and non-
pharmacological management is essential for good clinical 
outcomes in axial SpA. Physical activity (PA) and exercise, 
a subcategory of PA, are key aspects in the management of 
people with axial SpA [3, 4]. People with axial SpA are at 
increased risk of cardiovascular disease [5]. A lack of PA 
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and predominance of sedentary behaviour (SB), are inde-
pendent risk factors for co-morbidities, such as cardiovas-
cular disease, in the general population [6] and, therefore, 
should be considered in axial SpA symptom and co-mor-
bidity management.
Recently, disease activity was found to be associated 
with time spent sedentary while no association was found 
with moderate-vigorous physical activity (MVPA) in people 
with axial SpA [7]. In addition, physical fitness components 
(aerobic capacity, strength and body fat percentage) were 
associated with functional ability [8, 9] and disease activ-
ity [10]. Yet, the relationship between PA and/or SB with 
clinical measures such as spinal mobility, functional ability 
and exercise capacity in people with axial SpA is unknown. 
It is widely considered that people with axial SpA are less 
active and more sedentary than their healthy counterparts 
[11]. However, previous research has mainly focused on 
subjective methods of measuring PA and SB [11] and so 
may not be an accurate reflection [12]. While self-report 
measures are convenient and inexpensive, they are subject 
to issues such as recall bias and social desirability. Agree-
ment between commonly used questionnaires to measure PA 
and SB has been found to be poor [12, 13]. For instance, the 
International Physical Activity Questionnaire (IPAQ) under-
estimated sitting time by up to 4.6 h per day [12]. Therefore, 
the effects of PA and SB variables on health-related out-
comes may be diminished when using inaccurate measure-
ment tools [14]. The aim of this study was to explore the 
associations between objectively measured PA and SB with 
axial SpA clinical measures.
Methods
Study design and participants
This study utilises baseline data from a prospective cohort 
study on web-based physiotherapy exercise, which recruited 
50 people with axial SpA with low self-reported exercise 
levels (ClinicalTrials.gov ref: NCT02666313) [15]. The par-
ticipants were recruited from the secondary-care rheumatol-
ogy outpatient service of NHS Greater Glasgow & Clyde, 
UK. Participants were included if they had a confirmed 
diagnosis, by a rheumatology consultant, according to the 
Assessment of Spondyloarthritis International Society crite-
ria [16], for more than one year, were over 18 years and had 
access to the internet at home. Participants were excluded if 
they self-reported participating in structured exercise regu-
larly (three or more times per week), had a joint replacement 
within the last six months, had any significant comorbidi-
ties that would preclude them from taking part in a regular 
exercise programme or if they were currently participating 
in another clinical trial [15]. All participants gave informed, 
written consent and the study was approved by the West of 
Scotland Research Ethics Committee (Ref: 15/WS/0229).
Measurement of physical activity and sedentary 
behaviour
PA, defined as any bodily movement produced by skele-
tal muscle that requires energy expenditure [17], and SB, 
defined as any waking behaviour characterised by an energy 
expenditure of ≤ 1.5 metabolic equivalents while in a sitting, 
reclining or lying position [18], were objectively measured 
using the activPAL3 activity monitor (PAL Technologies 
Ltd, Glasgow, UK). The activPAL3 device is a small, light-
weight (55 × 35 × 7 mm, 15 g) tri-axial accelerometer worn 
on the anterior thigh of the dominant leg and attached using 
a Tegaderm waterproof dressing. The activPAL3 has been 
found to be a valid measure of steps, walking and sedentary 
time in healthy adults [19-21]. Participants were asked to 
wear the monitor continuously for one week and undertake 
their usual activities. A day was considered valid if it con-
tained 24 h of wear time. For each participant the time spent 
standing, walking, number of steps and time spent sedentary 
per day were measured. Participants were asked to record 
their sleep time each night using a sleep diary, and sleep 
time was removed from the analysis [22].
Demographic variables and outcome measures
Demographic characteristics including age, gender, work 
status and medication history were collected. Clinical meas-
ures included the following, described in full in Paul et al. 
[15]: Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI), a six item questionnaire measuring disease 
activity with higher scores indicating greater activity [23], 
Bath Ankylosing Spondylitis Functional Index (BASFI), 
a 10 item questionnaire measuring functional ability with 
higher scores indicating worse function [24], Bath Anky-
losing Spondylitis Metrology Index (BASMI), a five item 
index measuring spinal mobility with higher scores indi-
cating greater limitations in movement [25], Ankylosing 
Spondylitis Quality of Life (ASQOL), a questionnaire with 
higher scores indicating poorer quality of life [26],and the 
Six Minute Walk Test (6MWT), a walking test conducted 
over six minutes with a greater distance walked indicating 
better exercise capacity [27].
Statistical analysis
PA and SB data were extracted from the activPAL3 moni-
tors using proprietary software (version 7.24, PAL Tech-
nologies, Glasgow, UK). Data were visually inspected hour 
by hour and compared to completed sleep diaries to ensure 
accuracy of completed diaries. Additional data processing 
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(after activity classification by proprietary software) was 
conducted to remove sleep time using the HSC analysis pro-
gram (Version 15.32, Microsoft Excel, Microsoft Corpora-
tion, Redmond, WA, USA). A cadence of 100 steps/minute 
or above was used to represent time spent in MVPA [28, 29] 
and sitting events of 30 min or longer were used to define 
prolonged sitting [30, 31]. Data analysis was performed 
using SPSS version 25.0 (SPSS, IBM Corp, Armonk, NY, 
USA). Descriptive statistics were calculated to summarise 
all outcomes. All outcomes were assessed for normality 
using the Kolmogorov Smirnov test. Correlations between 
PA and SB with the BASFI, BASMI, BASDAI, ASQOL, 
and 6MWT were assessed using Pearson’s correlation coef-
ficient if normally distributed. Where data were not normally 
distributed, Spearman’s Rho correlation was used. Corre-
lations of ≥ 0.30, ≥ 0.50 and ≥ 0.70 were considered small, 
moderate and large, respectively [32]. The level of signifi-
cance was set at 5%.
Results
Fifty participants were recruited between December 2016 
and December 2017. PA and SB data were missing for five 
participants [allergy to Tegaderm dressing (n = 1), instru-
ment error (n = 3) and researcher error (n = 1)]; therefore, 
complete data were available for 45 participants. Complete 
activPAL3 data for seven (n = 1), six (n = 42), five (n = 1) 
and four days (n = 1) was available. Participants, 23 male 
and 22 female, had an average age of 49 ± 12 years and 
an average axial SpA disease duration of 16 ± 11 years 
(Table 1). The majority of participants (69%) were in paid 
employment with only 8% currently receiving physiotherapy 
treatment or attending an exercise class. Participants had 
an average BASDAI score of 4.5 ± 2.3, of which 28 par-
ticipants had a BASDAI of ≥ 4, indicating active disease 
activity [33] (Table 1). Distance walked during the 6MWT 
was 414 ± 106 m [range 121–622], substantially lower than 
the reference standard for healthy adults (571 ± 90 m [range 
380–782 m]) [34] (Table 1).
Participants walked on average for 93.2 ± 41.5  min/
day with an average of 7200 ± 3397 steps/day and average 
cadence of 69.6 ± 4.6 steps/min (Table 2). Approximately 
20 ± 4 min/day were spent stepping at a moderate intensity 
(> 100 steps/min). The majority of the waking day (65%) 
was spent sitting (10.8 ± 2.3 h/day). The majority of the total 
sitting time (40% ± 18% of the waking day) was accumulated 
in prolonged bouts (defined as sitting events ≥ 30 min) with 
an average of 6.7 ± 2.9 h/day of prolonged sitting bouts. On 
average, participants accumulated 121 ± 97 min/week of 
PA at a moderate intensity, with one third (n = 15) of par-
ticipants achieving the PA guidelines of 150 min/week of 
moderate intensity PA [35]. While there were no statistically 
significant differences between those with low and active 
disease activity (BASDAI), there was a trend for those with 
active disease activity to be less physically active and more 
sedentary (Table 2). There were no correlations of age and 
gender with any PA and SB outcomes.
There were small significant correlations for walking 
time and steps taken/day with the BASFI, indicating that 
both time spent walking and steps taken were associated 
with better function ability (BASFI, r = − 0.395, p = 0.007 
and r = − 0.404, p = 0.006, respectively). Similar signifi-
cant correlations were found for exercise capacity and 
walking time with steps taken/day (6MWT, r = 0.396, 
p = 0.007 and r = 0.421, p = 0.004, respectively) and qual-
ity of life (ASQOL, r = − 0.375, p = 0.011 and r = − 0.361, 
p = 0.015, respectively) (Table 3). In addition, time spent 
in MVPA was associated with better functional ability 
(BASFI, rho = − 0.358, p = 0.016) and exercise capacity 
Table 1  Participant characteristics
n number, SD standard deviation, m metres, M male, F female, BMI 
Body Mass Index, TNF Tumour Necrosis Factor, NSAIDs Non-Ste-
roidal Anti-Inflammatory Drugs, BASDAI Bath Ankylosing Spon-
dylitis Disease Activity Index, BASMI Bath Ankylosing Spondylitis 
Metrology Index, BASFI Bath Ankylosing Spondylitis Functional 
Index
n (%) Mean ± SD (range)
Demographics
 Age (years) 49.0 ± 11.7 (25–79)
 Gender (M:F) 23:22
 Duration of diagnosis (years) 15.6 ± 11.2 (1–45)
 BMI (kg/m2) 27.4 ± 5.6 (17.3–41.6)
Work status
 Paid employment 31 (69%)
 Retired/medically retired 9 (20%)
 Unemployed 3 (7%)





 Pain relief 22 (44%)
 Physio/exercise class 4 (8%)
Disease activity/mobility/function
 BASDAI (0–10) 4.5 ± 2.3 (0.4–8.7)
 Low disease activity (BAS-
DAI < 4)
17 (38%)
 Active disease activity (BAS-
DAI ≥ 4)
28 (62%)
 BASMI (0–10) 3.6 ± 1.8 (0.4–7.5)
 BASFI (0–10) 4.4 ± 2.6 (0.4–9.3)
Exercise capacity
 6 min walk test (m) 414 ± 106 (121–622)
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(6MWT, rho = 0.451, p = 0.002). Longer walking events 
were associated with better spinal mobility (BASMI, 
rho = −  0.352, p = 0.018), functional ability (BASFI, 
rho = − 0.316, p = 0.034) and exercise capacity (6MWT, 
rho = 0.404, p = 0.006) (Table 3). Furthermore, greater 
total time spent sitting was associated with poorer qual-
ity of life (ASQOL, r = 0.380, p = 0.010) and prolonged 
sitting was associated with reduced exercise capacity 
(6MWT, r = − 0.357, p = 0.016) (Table 3).
Table 2  Physical activity and sedentary behaviour outcomes for all participants and those categorised with low and active disease activity
n number, hrs hours, mins minutes, MVPA Moderate-Vigorous Physical Activity
All participants n = 45 
(% of waking hours)
Low disease activity (BAS-
DAI < 4) n = 17 (% of waking 
hours)
Active disease activity (BAS-
DAI ≥ 4) n = 28 (% of waking 
hours)
Waking hours (hrs) 16.6 ± 1.4 16.4 ± 1.0 16.7 ± 1.6
Sleep hours (hrs) 7.4 ± 1.4 7.6 ± 1.0 7.3 ± 1.6
Walking duration (mins/day) 93.2 ± 41.5 (9 ± 4%) 98.6 ± 39.6 (10 ± 4%) 90.0 ± 43.0 (9 ± 4%)
Standing duration (hrs/day) 4.2 ± 1.7 (26 ± 10%) 4.4 ± 1.5 (27 ± 9%) 4.2 ± 1.9 (25 ± 11%)
Sitting duration (hrs/day) 10.8 ± 2.3 (65 ± 13%) 10.4 ± 1.7 (63 ± 12%) 11.1 ± 2.6 (66 ± 14%)
Steps/day 7200 ± 3397 7615 ± 3212 6948 ± 3538
Steps/hour 436 ± 203 462 ± 192 419 ± 212
Walking duration at > 100 steps/min (mins/day) 20.3 ± 16.0 21.5 ± 15.7 19.6 ± 16.4
Mean steps/walking event 18.5 ± 6.2 18.1 ± 5.1 18.7 ± 6.9
Mean walking event cadence (steps/min) 69.6 ± 4.6 70.1 ± 5.4 69.3 ± 4.1
Mean MVPA (mins/week) 121 ± 97 128.9 ± 94.6 115.9 ± 99.1
Participants ≥ 150 mins of MVPA (n) 15/45 7/17 8/28
Sitting events (n/day) 49.1 ± 17.2 48.0 ± 14.7 49.8 ± 18.7
Prolonged sitting events > 30 min (n/day) 6.0 ± 2.0 5.8 ± 1.7 6.1 ± 2.1
Total duration of prolonged sitting > 30 min (h/day) 6.7 ± 2.9 (40 ± 18%) 6.3 ± 2.4 (38 ± 17%) 6.9 ± 3.2 (40 ± 17%)
Table 3  Correlations 
between physical activity and 
sedentary behaviour with 
axial spondyloarthritis clinical 
measures
The bold indicates associations with corresponding p value of less than or equal to 0.05
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASMI Bath Ankylosing Spondylitis 
Metrology Index, BASFI Bath Ankylosing Spondylitis Functional Index, ASQOL Ankylosing Spondylitis 
Quality of Life, 6MWT Six Minute Walk Test, MVPA Moderate-Vigorous Physical Activity, mins minutes
Variable BASDAI BASMI BASFI ASQOL 6MWT
Sleep hours r − 0.65 0.115 − 0.001 − 0.061 − 0.146
p 0.671 0.453 0.993 0.691 0.340
Walking time r − 0.162 − 0.197 − 0.395 − 0.375 0.396
p 0.288 0.195 0.007 0.011 0.007
Steps taken r − 0.167 − 0.220 − 0.404 − 0.361 0.421
p 0.272 0.147 0.006 0.015 0.004
Stand time r − 0.111 − 0.077 − 0.200 − 0.305 0.278
p 0.468 0.617 0.188 0.042 0.065
MVPA mins r − 0.189 − 0.235 − 0.358 − 0.254 0.451
p 0.213 0.120 0.016 0.092 0.002
Duration of walking events r − 0.058 − 0.352 − 0.316 − 0.095 0.404
p 0.707 0.018 0.034 0.536 0.006
Cadence of walking event r − 0.125 − 0.040 − 0.063 0.085 0.130
p 0.412 0.796 0.681 0.579 0.393
Sitting time r 0.180 0.048 0.289 0.380 − 0.235
p 0.236 0.796 0.054 0.010 0.120
Prolonged sitting event dura-
tion (> 30 min)
r 0.100 0.010 0.280 0.294 − 0.357
p 0.513 0.950 0.062 0.050 0.016
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Discussion
The results of this study indicate that, in people with axial 
SpA, higher levels of objectively measured PA (walking 
time, steps taken, MVPA, duration of walking events) is 
associated with better functional ability (BASFI), exercise 
capacity (6MWT) and spinal mobility (BASMI); while 
higher levels of objectively measured SB (greater total sit-
ting time and prolonged sitting) is associated with reduced 
exercise capacity (6MWT) and quality of life (ASQoL). 
While there was no association between SB or PA with dis-
ease activity (BASDAI). In this study, monitors were worn 
continuously which allowed for 24-h assessment which min-
imised data loss due to compliance or issues in identifying 
wear time [36]. Furthermore, the activPAL3 is recognised as 
the gold standard measurement device for postural SB [20, 
21], with sleep time, identified using diaries, removed from 
analysis. This method was of particular benefit as it avoided 
issues with differentiating between sleep, SB or non-wear 
time that may occur with other devices [36].
Participants with axial SpA in the current study engaged 
in a greater amount of SB (10.8 ± 2.3 h/day) than reported 
in previous research (7.5 ± 1.97 h/day) [7]. Swinnen et al. 
reported that people with axial SpA were sedentary for 
17.99 h/day including sleep time. If we assume sleep time 
of approximately 8 h/day then sedentary time in the cur-
rent study may be comparable. Participants in the current 
study spent less time spent in MVPA, 20.3 ± 16.0 min/day, 
compared to 59.1 ± 29.6 min/day [7] and 98 min/day [37]. 
These differences are likely due to differences in recruitment 
(participants in the current study were excluded if they self-
reported as exercising ≥ 3 times/week), while differences in 
measurement device and their position on the body or clas-
sification of MVPA may further play a role. For instance, 
O’Dwyer et al. [7] utilised the RT3 tri-axial accelerometer, 
worn at the hip for at least 10 h per day, removed during 
sleep and washing/bathing activities, providing an output 
expressed as activity counts and converted to minutes. This 
could have led to a systematic error in which SB was not 
consistently measured. Comparisons with other research 
[38-40], which only reported activity counts, cannot be made 
since they are arbitrary units which require calibration [40].
Participants in the current study undertook 7200 ± 3397 
steps/day with only 33% of participants meeting the current 
UK and USA PA guidelines (150 mins MVPA/week) [35, 
41]. This is similar to previous objectively measured find-
ings (27–39%) [7, 42], yet lower compared to studies which 
measured PA participation using questionnaires (41–71%) 
[43-45], suggesting participants may overestimate their PA 
levels when assessed by self-report. This rate of attainment 
is based upon PA guidelines for healthy adults (18–65 years 
old) since no disease-specific guidelines exist.
Engaging in regular PA and reducing prolonged SB is 
important to maintain and improve health [46]. This study 
adds to the current literature on PA and SB levels of people 
with axial SpA using accurate objectively measured PA and 
SB in people with axial SpA who self-report as not adhering 
to PA guidelines. The low adherence to the PA guidelines 
are concerning given the findings of the current study, risk 
of developing co-morbidities [5] and the beneficial effects 
of exercise [3]. The management of people with axial SpA 
should focus on interventions to improve PA to optimise 
the health benefit, and consider interventions to reduce SB.
This study has a number of limitations. First, selection 
bias may be present since studies investigating exercise and 
PA are likely to recruit participants who are interested in 
PA/exercise; while, potential participants recruited in the 
current study were excluded if they were exercising three 
or more times per week [15]. As such, the PA and SB levels 
presented may not be representative of the overall axial SpA 
population. Finally, the results presented are cross-sectional, 
therefore, prevent determination of causality with multiple 
comparisons conducted on a small sample with no statistical 
corrections employed.
Conclusion
The results demonstrate objective PA outcomes are asso-
ciated with better function (BASFI), exercise capacity 
(6MWT) and spinal mobility (BASMI), while SB outcomes 
are associated with exercise capacity (6MWT) and quality 
of life (ASQoL) in people with axial SpA. These findings 
appear to support the promotion of PA and reduction of SB 
in this population, as well as the use of objective measure-
ment devices for PA and SB in axial SpA. Future research is 
required to explore if interventions which improve PA and/
or SB result in improvements in clinical measures.
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